The CARMA study is evaluating ELC-301, an iTANK-armed CD20-targeting CAR T-cell therapy, in patients with relapsed or refractory B-cell lymphoma. The first dose cohort consisted of three patients treated with the lowest dose level, equivalent to one-tenth of the planned maximum dose.

Professor Magnus Essand, Chief Scientific Officer and co-founder of Elicera Therapeutics, will present the data at the SCRM in Malmö, Sweden. Highlights from the preliminary principal investigator-assessed outcomes include:

• Patient 1, achieved complete metabolic response at one-month assessment, and the response remained at the six-month follow-up.
• Patient 2, who had previously received standard CD19 CAR T-cell therapy, had possible progression at the three-month follow-up, to be confirmed.
• Patient 3, also previously treated with CD19 CAR T therapy, achieved a complete metabolic response at the one-month follow-up.

"We are thrilled with the early results from the CARMA study, where ELC-301 has successfully cleared all active lymphoma in two out of three treated patients, including one who had previously failed CD19 CAR T-cell therapy. This was achieved despite using a low dose in a challenging patient population," said Jamal El-Mosleh, CEO of Elicera Therapeutics. "These preliminary data, though from a small cohort, highlight the unique potential of our iTANK-armed CAR T-cell therapy and support our belief that ELC-301 may offer meaningful benefits where existing therapies fall short."

The CARMA study is continuing with patient enrollment at escalating dose levels to further assess safety, tolerability, and preliminary efficacy. Cohort 2 has already been initiated, with two patients treated so far at a dose level that is three times higher than that of Cohort 1. Additional preliminary data from this and subsequent cohorts will be reported as the study progresses and in connection with presentation at scientific conferences.